Answers are grounded in this paper and cite their sources.
To the Editor—We read with great interest the article by Shields and colleagues reviewing the available treatment options for carbapenem-resistant Acinetobacter baumannii (CRAB) infections [1]. With regard to the newly developed β-lactam agents, the authors concluded that sulbactam/durlobactam, if approved for clinical use, will become a front-line agent for the treatment of invasive CRAB infections. The authors also focused on the role of cefiderocol, considering the encouraging data from real-world clinical use [1]. Interestingly, among the reviewed traditional agents used in combination (polymyxins, sulbactam, and tetracyclines) the possible role of intravenous fosfomycin was not even mentioned. Considering a single trial conducted in 2014 on a relatively small sample, which failed to demonstrate the superiority of colistin plus fosfomycin over colistin alone [2], and also that intravenous fosfomycin is not currently available in several countries, the role of this antibiotic in the treatment of CRAB infection has been probably underinvestigated. Because colistin is transitioning from a backbone to a secondary agent in CRAB infection treatment, it appears important to identify which agents are best suited for a combination with the newly developed β-lactam agents. Considering also the limitations of polymyxins and tetracyclines in terms of pharmacokinetic, pharmacodynamic, and safety profile, intravenous fosfomycin could have several theoretical advantages over these competitors. As a matter of fact, this drug is characterized by good tissue penetration (including infected lung tissue) as well as a good concentration in serum, urine, and cerebrospinal fluid, with a good safety profile [3].
No takes yet. Share an insight, caveat, or question.
Guastalegname et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: